Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EZH2 Y646F||lymphoma||sensitive||EZH2 inhibitor||Tazemetostat||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with Tazverik (tazemetostat) inhibited proliferation and promoted cell death in lymphoma cell lines harboring EZH2 Y646F in culture, and decreased tumor H3K27Me3 levels in cell line xenograft models (PMID: 24563539).||24563539|
|EZH2 Y646F||follicular lymphoma||sensitive||EZH2 inhibitor||Tazemetostat||FDA approved - On Companion Diagnostic||Actionable||In a Phase II trial that supported FDA approval, Tazverik (tazemetostat) treatment was well-tolerated, resulted in a median progression-free survival of 11.1 months, objective response in 77% (33/43), and stable disease in 23% (10/43) of patients with relapsed or refractory follicular lymphoma, who had two or more prior therapies and harbored EZH2 mutations as detected by an approved test, including EZH2 Y646F (Blood (2019) 134 (Supplement_1):123; NCT01897571).||detail... detail... detail...|
|EZH2 Y646F||diffuse large B-cell lymphoma||sensitive||EED226||Preclinical - Cell culture||Actionable||In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646F demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).||28135235|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|